[HTML][HTML] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
[HTML][HTML] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo, M Del Vecchio… - … for ImmunoTherapy of …, 2020 - jitc.bmj.com
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo, M Del Vecchio… - … for ImmunoTherapy of …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background</jats: title>< jats: p> In the KEYNOTE-022 study,
pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival …
pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival …
KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo, M Del Vecchio… - … for Immunotherapy of …, 2020 - pure.au.dk
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - Journal for …, 2020 - search.proquest.com
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - Journal for …, 2020 - pubmed.ncbi.nlm.nih.gov
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
[引用][C] KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - Journal for …, 2020 - espace.library.uq.edu.au
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo, M Del Vecchio… - ikm.ku.dk
BACKGROUND: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - … for ImmunoTherapy of …, 2020 - escholarship.org
In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet)
improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib …
improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib …
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
PF Ferrucci, AM Di Giacomo, M Del Vecchio… - … for Immunotherapy of …, 2020 - europepmc.org
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …